
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A long-held theory among HIV treatment experts is that a short course of antiretroviral drugs given during the first few weeks after infection--a period commonly called acute or primary infection--could provide long-term benefits, including slowing or even preventing CD4-cell loss. That theory, however, took a significant hit in two new studies. The first, published in the journal AIDS, showed that although a short course of anti-HIV drugs begun within six months of infection did initially boost CD4 counts, it did not delay the need for standard antiretroviral therapy later on. The second research project, published in the Journal of Acquired Immune Deficiency Syndromes, showed that taking the meds even earlier--within three months of infection--still was ineffective in preventing eventual CD4-cell loss or slowing the rate of later cellular decline.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
November 28 2023 5:32 PM
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
November 28 2023 11:55 AM
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
HIV Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.